IPA ImmunoPrecise: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
To ensure the preservation of biomaterials, ImmunoPrecise Antibodies (IPA) has established a network of specialized air transport with strict temperature controls. The stock's price history helps track the efficiency of these processes, while the EV/EBITDA stands at . The business relies on powerful lobbying and an exclusive AI antibody discovery system, creating significant barriers to entry for competitors. Growth for ImmunoPrecise Antibodies (IPA) is driven by partnerships with major players and the implementation of BioStrand to optimize R&D.
Summary analytical data breakdowns for immunoprecise.com (IPA)
- market price and analyst price targets:
- company stock capitalization data:
- book value of equity indicators:
- debt burden and liquidity indicators:
Total Debt to Capital ImmunoPrecise Antibodies|IPA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital ImmunoPrecise Antibodies Ltd.|IPA - Company Total Debt Obligations|Debt to Book Capitalization Ratio ImmunoPrecise Antibodies Ltd.|IPA - Long-Term Debt Volume|Company Short-Term Debts ImmunoPrecise Antibodies|Quick Liquidity Indicator immunoprecise.com
- business earnings and investment ratios data:
IPA - Final Profit|Projected Future Earnings ImmunoPrecise Antibodies|IPA - P/E Multiple|Future Price to Earnings ImmunoPrecise Antibodies Ltd.|IPA - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio ImmunoPrecise Antibodies Ltd.|IPA - Company profit before taxes, interest and amortization|Net earnings per share (EPS TTM) ImmunoPrecise Antibodies|IPA - Net earnings per share for the last four quarters|Quarterly EPS earnings growth immunoprecise.com|IPA - Earnings per share growth in current year|Net earnings per share growth forecast for next year ImmunoPrecise Antibodies
Comprehensive company analysis:IPA (ImmunoPrecise)
Investors utilize fundamental benchmarks to determine the fair value of assets with high debt loads. This metric compares the total enterprise value, including debt, with operating profit before depreciation and amortization to identify undervalued companies. By analyzing changes in the EV/EBITDA multiple, one can assess the efficiency of the digital logistics at ImmunoPrecise Antibodies (IPA), which reduces R&D expenses and optimizes capitalization by accelerating pharmaceutical supply chains.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to Operating Income Before Depreciation Ratio RGEN|Avidity Biosciences, Inc. (RNA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|WGS (Sema4) - EV/EBITDA Multiple|Company Value to EBITDA Ultragenyx Corp RARE|EV/EBITDA Multiple BEAM|Enterprise Value to EBITDA Ratio sarepta.com SRPT|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics Inc (TXG)|NTLA - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio Stoke Corp STOK|BLFS: EV/EBITDA Multiple|Company Value to EBITDA wavelifesciences.com (WVE)|Enterprise Value to EBITDA Ratio MAZE|SION: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple PRME|EV/EBITDA Multiple Taysha Corp (TSHA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure N.V. QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|RGNX: Enterprise Value to EBITDA Ratio|Solid Biosciences Inc - Enterprise Value to Operating Income Before Depreciation Ratio|OCGN: EV/EBITDA Multiple|PACB - Total Company Value to Operating Income Before Depreciation Ratio|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization DSGN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Rocket Pharmaceuticals, Inc. (RCKT)|FDMT - Company Value to EBITDA|EV/EBITDA Multiple LXEO (Lexeo Therapeutics, Inc.)|KRRO: Enterprise Value to Operating Income Before Depreciation|Editas Medicine, Inc. - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio silence-therapeutics.com SLN|PRQR: EV/EBITDA Multiple|Company Value to EBITDA Codexis (CDXS)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sangamo|Nautilus Biotechnology Inc (NAUT) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple MGX|Total Company Value to Operating Income Before Depreciation Ratio precisionbiosciences.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Generation Bio GBIO|BOLD (Boundless Bio Inc.) - Company Value to Operating Income Before Depreciation Ratio|Exicure Corp - EV/EBITDA Multiple|IMNN - EV/EBITDA Multiple|PHIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation MBIO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TransCode Therapeutics Inc.|Enterprise Value to Operating Income Before Depreciation BNGO (Bionano)|EV/EBITDA Multiple APDN|EV/EBITDA Multiple bluebird bio, Inc (BLUE)|EV/EBITDA Multiple OMGA (Omega Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio singulargenomics.com (OMIC)|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Syros Pharmaceuticals Inc. (SYRS) - Enterprise Value to EBITDA Ratio|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio TRACON Pharmaceuticals, Inc|Enterprise Value to EBITDA Ratio UBX
